Hänninen, K. http://orcid.org/0000-0001-9642-2598
Viitala, M.
Atula, S.
Laakso, S. M.
Kuusisto, H.
Soilu-Hänninen, M.
Funding for this research was provided by:
The Finnish Multiple Sclerosis Foundation
Turku University Foundation
Turku University State Research Funding
University of Turku (UTU) including Turku University Central Hospital
Article History
Received: 22 April 2021
Revised: 12 June 2021
Accepted: 15 June 2021
First Online: 25 June 2021
Declarations
:
: S Atula has received honoraria for lectures, advisory boards or for serving as an investigator for clinical trials from Biogen, Novartis, Merck and Roche. H Kuusisto has received honoraria for lectures, advisory boards or for serving as an investigator for clinical trials from Biogen, Celgene, Genzyme, Novartis, Merck, Roche and Sanofi. M Soilu-Hänninen has received honoraria for lectures, advisory boards or for serving as an investigator for clinical trials from Biogen, Celgene, Genzyme, Novartis, Merck, Roche, Sanofi and Teva. SM Laakso has received honoraria for lectures from Merck and congress expenses covered by Roche and Merck. K Hänninen and M Viitala have no disclosures.
: According to Finnish law, ethics committee approval was not required since the study was based on administrative register data and did not involve any contact with patients. The study was approved by the Turku, Helsinki and Tampere University Hospital and Kanta-Häme Central Hospital Research Services. The data processing practices followed the EU Data Protection Directive rules (permission numbers T16/2017 for SwF, HUS/163/2019 for Helsinki, R19613S for Pirkanmaa and KHSHP/1571/13.00.01/2018 for Kanta-Häme).